Biosimilar is a type of biological product that is almost exactly the same as the original product whose patent has expired. The development and testing of biosimilars are important parts of the whole process of making a drug. Regulation for copycat drugs is an important part of making sure that both original and biosimilar drugs work well and don't interfere with each other. As biosimilars have a complicated structure, are made in more than one step, and might cause an immune response, they have to go through different regulatory processes before they can be sold.
The Biosimilar Pipeline Analysis Market is growing because there are a lot of different kinds of cancer and people need treatments that are cheap and work well. Over the next few years, the market is likely to grow because more biosimilars are getting approved. There are a number of licensed biologics on the market, but they cost so much that most people can't afford them. This pushed the market for biosimilars in the right direction. Biosimilars need complicated infrastructure to be made, and the clinical trial and approval process takes a long time. These are the main problems that the biosimilar pipeline research market has to deal with.
Major Players in the Biosimilar Pipeline Analysis Industry:
1. Biocon
Biocon is an Indian biopharmaceutical company based in Bangalore. It was founded in 1978 and headquartered in Karnataka, India. It operates in approximately 120 countries. In November 2022, Biocon Biologics Ltd., a subsidiary of Biocon Ltd., revealed that it had completed its multi-billion-dollar (USD) purchase of its partner Viatris Inc.'s global biosimilars business.
2. Pfizer Inc.
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation, founded in 1849. The headquarter is in Williamsburgh, New York. It operates to over 181 countries. Pfizer Inc. shared updates on the Company's multifaceted efforts to combat the COVID-19 pandemic as part of a two-day virtual Investor Day in September 2020. These updates included new data on the BNT162b2 vaccine candidate that is being developed in partnership with BioNTech SE. The company expects a revenue CAGR of at least 6% over the following five years, as well as the delivery of longer-term top-line growth after that time. The pipeline updates help the company achieve these goals.
3. F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd which is commonly known as Roche is a Swiss multinational healthcare company, founded in 1896. The company headquarters are located in Basel, Switzerland. It actively operates in over 130 countries.
4. Amgen Inc.
Amgen Inc. is an American multinational biopharmaceutical company founded in 1980 and is headquartered in California, United States. It operates in 100 countries and has global presence. Amgen announced in June 2023 that new data from the CodeBreaK clinical trial program, the most comprehensive global development program for patients with KRAS G12C-mutated cancers, would be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The presented research supports the efficacy of LUMAKRAS®/LUMYKRAS® (sotorasib) in the treatment of advanced non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC).
5. Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH is one of the world's largest pharmaceutical companies, and the largest private one. It was founded in 1885 and headquartered in Ingelheim, Germany .It operates in 108 countries.
6. AstraZeneca
AstraZeneca is a British-Swedish multinational pharmaceutical and biotechnology company. It was founded in 1999 and headquartered in England, UK. It operates in. AstraZeneca advances its pipeline and highlights advancements in immuno-oncology, ADCs, cell therapy, and epigenetics at the AACR in April 2023.In the AEGEAN Phase III trial, a novel Imfinzi-based regimen substantially improved patient outcomes for resectable non-small cell lung cancer.
7. Novartis AG
Novartis AG was created in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis had its headquarters at Basel, Switzerland. It improves and prolongs lives. Novartis AG has partners in about 140 countries. Sandoz, a global leader in off-patent (generic and biosimilar) medicines, announced a multi-year partnership with Seattle-based Just - Evotec Biologics, a subsidiary of Evotec SE, in May 2023. The agreement covers the development and manufacture of multiple biosimilar medicines, with an option for expansion, and is the most recent step towards Sandoz's consolidation as an independent off-patent medicines company.
8. Merck & Co.
Merck & Co. is an American multinational pharmaceutical company and is named for Merck Group, was founded in 1668, and headquartered in New Jersey, United States. It operates in 66 countries. Merck, also known as MSD outside the United States and Canada, announced in February 2020 its intention to spin-off its Women's Health, trusted Legacy Brands, and Biosimilars businesses into a new, as-yet-unnamed, publicly traded corporation. The spinoff will enable both management teams to be more responsive to the specific requirements of their patients and customers and to achieve faster growth by utilizing operating models that are tailored to these needs.
Definition: A biosimilar is a biologic medical product that is almost an identical copy of an original product that is manufactured by a different company.
